Chloroform → (6-Bromopyridin-3-yl)[4-(p-tolyloxy)piperidin-1-yl]methanone

HRID 1803965

反応式

HRID 1803965 の反応式
[C:1]1([CH3:14])[CH:6]=[CH:5][C:4]([O:7][CH:8]2[CH2:13][CH2:12][NH:11][CH2:10][CH2:9]2)=[CH:3][CH:2]=1.[Br:15][C:16]1[CH:24]=[CH:23][C:19]([C:20](O)=[O:21])=[CH:18][N:17]=1.O.[Cl-].COC1N=C(OC)N=C([N+]2(C)CCOCC2)N=1.C(Cl)(Cl)Cl>CO>[Br:15][C:16]1[N:17]=[CH:18][C:19]([C:20]([N:11]2[CH2:12][CH2:13][CH:8]([O:7][C:4]3[CH:3]=[CH:2][C:1]([CH3:14])=[CH:6][CH:5]=3)[CH2:9][CH2:10]2)=[O:21])=[CH:23][CH:24]=1

参加物

6

反応物 4

HCID 6212ChloroformHCID 2389326-Bromonicotinic acidHCID 38374974-(4-Methylphenoxy)piperidineHCID 231494114-(4,6-Dimethoxy[1.3.5]triazin-2-yl)-4-methylmorpholinium chloride hydrate

生成物 1

HCID 58484591(6-Bromopyridin-3-yl)[4-(p-tolyloxy)piperidin-1-yl]methanone収率 99.9%

試薬・触媒・溶媒 1

HCID 887Methanol溶媒

実験手順

To a mixture of 4-(p-tolyloxy)piperidine (765 mg), 6-bromonicotinic acid (808 mg) and 4-(4,6-dimethoxy[1.3.5]triazin-2-yl)-4-methylmorpholinium chloride hydrate (DMT-MM) (1.7 g) were added chloroform (5 mL) and methanol (5 mL), and the mixture was stirred at room temperature overnight. After evaporation of the solvent, the residue was purified by column chromatography (chloroform:methanol) to give the title compound (1.5 g).

後処理

  1. customAfter evaporation of the solvent
  2. customthe residue was purified by column chromatography (chloroform:methanol)

出典と根拠

ORDレコード
ord-31d277f31d42413fbaa18166042e1a7d
出典データセット
uspto-grants-2013_01
特許番号
US08354401B2

関連ノート

読み込み中…